Probiotics for Atopic Dermatitis
Verdict: Published with Warning
Across 6 PubMed studies, the evidence for Probiotics in Atopic Dermatitis grades Tier C — weak evidence. Effective, but with safety or population caveats.
C 🟠 C Weak Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.43
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
77%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.431
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 1 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Probiotics for treating eczema (Cochrane Database of Systematic Reviews, Makrgeorgou et al.)
Finding: On the patient-relevant primary outcomes probiotics made little or no difference (symptoms MD -0.44 on 0-20, 95% CI -1.22 to 0.33, moderate-certainty; QoL SMD 0.03, 95% CI -0.36 to 0.42, low-certainty), and although clinician-rated SCORAD fell 3.91 points (95% CI -5.86 to -1.96) this is below the ~8.7-point minimal clinically important difference, so the review concluded probiotic treatment of eczema is not evidence-based.
View on PubMed The impact of prebiotics, probiotics and synbiotics on the prevention and treatment of atopic dermatitis in children: an umbrella meta-analysis (Frontiers in Pediatrics)
Finding: Umbrella synthesis found probiotics/synbiotics reduced AD incidence (RR 0.74, 95% CI 0.70-0.79) and modestly lowered clinician-rated SCORAD (WMD -3.75, 95% CI -5.08 to -2.42), but the severity effect is a sub-MCID surrogate and rests on highly heterogeneous primary studies.
View on PubMed Single-Strain Probiotic Lactobacilli for the Treatment of Atopic Dermatitis in Children: A Systematic Review and Meta-Analysis (Pharmaceutics)
Finding: Single-strain lactobacilli significantly reduced SCORAD versus placebo (MD -4.50, 95% CI -7.50 to -1.49; p=0.003) but with very high heterogeneity (I2=90%) and a magnitude below the SCORAD MCID, so clinical relevance is uncertain.
View on PubMed Therapeutic effectiveness of probiotics for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials with subgroup analysis (Asian Pacific Journal of Allergy and Immunology)
Finding: Probiotics produced a statistically significant SCORAD decrease (SMD -4.0, 95% CI -7.3 to -0.7), with larger effects for >3-month supplementation (SMD -5.1) and Lactobacillus formulations (SMD -4.4), but the wide CIs and surrogate endpoint temper clinical certainty.
View on PubMed Meta-analysis on preventive and therapeutic effects of probiotic supplementation in infant atopic dermatitis (Journal der Deutschen Dermatologischen Gesellschaft)
Finding: Probiotics lowered AD incidence by 22% overall (and up to 49% when given to pregnant/lactating mothers) and improved SCORAD, but had no effect on infant quality of life (IDLQI) and a less conclusive treatment effect in infants under 1 year.
View on PubMed Topical Probiotics Reduce Atopic Dermatitis Severity: A Systematic Review and Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials (Cureus)
Finding: Despite the optimistic title, the pooled 4-week analysis showed NO significant difference in SCORAD between topical probiotics and control (SMD -0.292, 95% CI -0.904 to 0.321; p=0.350), and the evidence base is very small (4 trials, ~93 participants).
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
FDA has not approved any probiotic product for use as a drug or biological product in infants of any age source↗
L4b EU EFSA
Against
a cause and effect relationship had not been established between the consumption of a combination of bacterial strains and reduction of gastro-intestinal discomfort source↗
L4c UK NHS
Cautious
There's some evidence that probiotics may be helpful in some cases, such as helping to ease some symptoms of irritable bowel syndrome (IBS). But there's little evidence to support many health claims made about them. source↗
L4d TW TFDA / 衛福部
Supportive
益生菌屬食品，並無治療疾病的效果 source↗
L4e WHO
Neutral
probiotic supplementation with the strains Bifidobacterium longum subsp. Infantis DSM33361 and Lactobacillus rhamnosus GG source↗
L5a NIH Office of Dietary Supplements
Supportive
Probiotics might reduce some symptoms of IBS. source↗
L5c Cleveland Clinic
Cautious
Probiotic products probably won't solve these skin issues completely. There are likely several factors that contribute to your symptoms. But an imbalance of the skin's bacteria might be one piece of the puzzle. source↗
L5e Specialty Society (condition-mapped)
Against
Conditional recommendations are made against early food introduction, human milk consumption, and probiotic or vitamin D supplementation for AD prevention. source↗